Whether or not you are an Ensho user, it is possible to participate in this program. However, timelines will vary. The enrolment process is quickest if you are already an Ensho user. If you are not enrolled but use one of the following EHRs, sign-up and initial analysis should still take place within a matter of weeks:

• Accuro
• Oscar Pro
• IndiviCare
• Healthquest
• Cerebrum

Contact aim-lo@eocihealth.com if you have questions about participating.

This activity will allow participants to:

• Assess how they manage their patients with ASCVD and dyslipidemia
• Evaluate their adherence to guidelines
• Improve their practice by providing them with individual reports of patient who would benefit from treatment intensification and added testing
• Consider recommendations offered by planning committee
• Compare their practice to a national aggregate of other cardiologists

Once a month and every quarter for 12 months, participants receive individual and aggregate reports of patients with ASCVD who are not optimized on GDMT for lipid management. Reports are available to clinic administrators in the Ensho Health web application and sent directly to physicians via fax, as well as email (if requested).

Participants also have access to educational resources designed by the Scientific Committee to help improve treatment optimization.

Patients with:

• LDL-C ≥1.8mmol/L with ASCVD who have ever been prescribed a statin

With one or more risk factors:

• ACS, including STEMI or NSTEMI in past 2 years
• Clinically evident ASCVD
• Diabetes mellitus or metabolic syndrome
• Polyvascular disease (vascular disease in ≥ 2 arterial beds)
• Symptomatic PAD
• Previous CABG surgery
• Heterozygous FH

Report includes:

Lipids Profile (single most recent entry in the EHR)

• LDL-C
• Triglycerides
• Non-HDL
• HDL
• Lp(a)
• ApoB

Current Medication(s) and Dose(s):

• Statins
• Ezetimibe
• PCSK9 inhibition mAbs
• PCSK9 inhibition siRNA
• Icosapent Ethyl

• If LDL-C is ≥1.8 mmol, recommendation to add-on therapies to statins
• If triglycerides are ≥1.5 mmol, consideration of adding icosapent ethyl
• If there is no Lp(a) measurement on file, recommendation to measure it once in the lifetime of the patient
• If ApoB measurements is not available from last lipid panel and triglycerides are ≥1.5 mmol, recommendation to order ApoB test at next lipid panel

• No more long lists of patients to optimize - adding stress and time to your already busy schedule:
  • You will get a list every 30 days of patients who require lipid-lowering treatment intensification and are already scheduled for a visit in the next month
• Simple but detailed and well-identified reports that do not require you to match a file number to a patient name
• No agreements, contracts, forms, or phone calls to sign-on to the program

1. Every 30 days for 1 year:

• Individual reports for each patient who already has an appointment scheduled with you in the next 30 days and requires treatment intensification for lipid-lowering

2. Every 3 months for 1 year:

• Overview report with aggregate data and patient-level data from:
  • Patients seen in last 3 months
  • Patients with appointment in the next 3 months

Results are available to clinic administrators in the Ensho Health web application and sent directly to physicians via fax, as well as email (if requested).

Yes. This program has been reviewed and approved by Optimum, an independent ethics review board, including approval to waive the need for individual patient consent, as there is no risk to patients (file no 1005). Approval letter is available upon request.

Financial Disclosure

Novartis Canada is providing financial support to the CPD-Network for this initiative, but neither the program sponsor, the scientific committee, the program organizer, or anyone else will have access to your individual patient-level data. By electing to participate in AIM-LO, you agree that an aggregate and anonymized report summarizing the findings can be shared with the scientific committee and EOCI.